RecruitingPhase 2NCT02393157
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
Studying Non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- New York Medical College
- Principal Investigator
- Mitchell Cairo, MD, MDNew York Medical College
- Intervention
- Obinutuzumab(drug)
- Enrollment
- 25 enrolled
- Eligibility
- 3-31 years · All sexes
- Timeline
- 2015 – 2027
Study locations (1)
- New York Medical College, Valhalla, New York, United States
Collaborators
Roswell Park Cancer Institute
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02393157 on ClinicalTrials.govOther trials for Non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07222631SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin LymphomasUniversity of California, San Diego
- RECRUITINGNCT07313943PAX5-NEGATIVE HODGKIN-LIKE LYMPHOMAS: A DIAGNOSTIC CHALLANGEIRCCS Azienda Ospedaliero-Universitaria di Bologna
- RECRUITINGPHASE2NCT07283822Amping up With PemJAKSeda S. Tolu
- RECRUITINGNANCT06923397Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND TrialDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT06854003BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaChristine Ryan
- ACTIVE NOT RECRUITINGPHASE1NCT06622226A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin LymphomaOno Pharmaceutical Co. Ltd
- RECRUITINGPHASE1NCT06522932PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T TherapyMichael Randall
- RECRUITINGPHASE1NCT06420089CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)Vittoria Biotherapeutics